Lu AA47070
Lu AA47070 is a selective adenosine A 2A receptor antagonist that was under development for the treatment of Parkinson's disease but was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lu AA47070 is a selective adenosine A 2A receptor antagonist that was under development for the treatment of Parkinson's disease but was never marketed. It has been found to reverse some of the effects of dopamine D 2 receptor antagonists like pimozide and haloperidol, for instance tremulous jaw movements, catalepsy, locomotor suppression, and other anti-motivational effects, in animals.
The drug is a prodrug of Lu AA41063. It was discontinued in phase 1 clinical trials because it lacked the intended pharmacological properties in humans. Lu AA47070 was first described by 2008.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1328680938 under CC BY-SA 4.0; modifications have been made.